J 2016

Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis

RAMASWAMY, Vijay; Thomas HIELSCHER; Stephen C. MACK; Alvaro LASSALETTA; Tong LIN et al.

Základní údaje

Originální název

Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis

Autoři

RAMASWAMY, Vijay; Thomas HIELSCHER; Stephen C. MACK; Alvaro LASSALETTA; Tong LIN; Kristian W. PAJTLER; David T.W. JONES; Betty LUU; Florence M.G. CAVALLI; Kenneth ALDAPE; Marc REMKE; Martin MYNAREK; Stefan RUTKOWSKI; Sridharan GURURANGAN; Roger E. MCLENDON; Eric S. LIPP; Christopher DUNHAM; Juliette HUKIN; David D. EISENSTAT; Dorcas FULTON; Frank K. H. van LANDEGHEM; Mariarita SANTI; Marie-Lise C. van VEELEN; Erwin G. VAN MEIR; Satoru OSUKA; Xing FAN; Karin M. MURASZKO; Daniela P.C. TIRAPELLI; Sueli M. OBA-SHINJO; Suely K.N. MARIE; Carlos G. CARLOTTI; Ji Yeoun LEE; Amulya A. Nagesware RAO; Caterina GIANNINI; Claudia C. FARIA; Sofia NUNES; Jaume MORA; Ronald L. HAMILTON; Peter HAUSER; Nada JABADO; Kevin PETRECCA; Shin JUNG; Luca MASSIMI; Massimo ZOLLO; Giuseppe CINALLI; László BOGNÁR; Almos KLEKNER; Tibor HORTOBÁGYI; Sarah LEARY; Ralph P. ERMOIAN; James M. OLSON; Jeffrey R. LEONARD; Corrine GARDNER; Wieslawa A. GRAJKOWSKA; Lola B. CHAMBLESS; Jason CAIN; Charles G. EBERHART; Sama AHSAN; Maura MASSIMINO; Felice GIANGASPERO; Francesca R. BUTTARELLI; Roger J. PACKER; Lyndsey EMERY; William H. YONG; Horacio SOTO; Linda M. LIAU; Richard EVERSON; Andrew GROSSBACH; Tarek SHALABY; Michael GROTZER; Matthias A. KARAJANNIS; David ZAGZAG; Helen WHEELER; Katja von HOFF; Marta M. ALONSO; Teresa TUON; Ulrich SCHÜLLER; Karel ZITTERBART; Jaroslav ŠTĚRBA; Jennifer A. CHAN; Miguel GUZMAN; Samer K. ELBABAA; Howard COLMAN; Girish DHALL; Paul G. FISHER; Maryam FOULADI; Amar GAJJAR; Stewart GOLDMAN; Eugene HWANG; Marcel KOOL; Harshad LADHA; Elizabeth VERA-BOLANOS; Khalida WANI; Frank LIEBERMAN; Tom MIKKELSEN; Antonio M. OMURO; Ian F. POLLACK; Michael PRADOS; H. Ian ROBINS; Riccardo SOFFIETTI; Jing WU; Phillipe METELLUS; Uri TABORI; Ute BARTELS; Eric BOUFFET; Cynthia E. HAWKINS; James T. RUTKA; Peter DIRKS; Stefan M. PFISTER; Thomas E. MERCHANT; Mark R. GILBERT; Terri S. ARMSTRONG; Andrey KORSHUNOV; David W. ELLISON a Michael D. TAYLOR

Vydání

Journal of Clinical Oncology, Alexandria, American Society of Clinical Oncology, 2016, 0732-183X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 24.008

Kód RIV

RIV/00216224:14110/16:00092056

Organizační jednotka

Lékařská fakulta

UT WoS

000381497000006

EID Scopus

2-s2.0-84978701824

Klíčová slova anglicky

CONFORMAL RADIATION-THERAPY; NEWLY-DIAGNOSED EPENDYMOMA; PHASE-II TRIAL; BRAIN-TUMORS; PEDIATRIC-PATIENTS; CRANIAL RADIATION; CHILDREN; CHILDHOOD; CHEMOTHERAPY; AGE

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 1. 12. 2016 11:49, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Purpose Posterior fossa ependymoma comprises two distinct molecular variants termed EPN_PFA and EPN_PFB that have a distinct biology and natural history. The therapeutic value of cytoreductive surgery and radiation therapy for posterior fossa ependymoma after accounting for molecular subgroup is not known.MethodsFour independent nonoverlapping retrospective cohorts of posterior fossa ependymomas (n = 820) were profiled using genome-wide methylation arrays. Risk stratification models were designed based on known clinical and newly described molecular biomarkers identified by multivariable Cox proportional hazards analyses. Results Molecular subgroup is a powerful independent predictor of outcome even when accounting for age or treatment regimen. Incompletely resected EPN_PFA ependymomas have a dismal prognosis, with a 5-year progression-free survival ranging from 26.1% to 56.8% across all four cohorts. Although first-line (adjuvant) radiation is clearly beneficial for completely resected EPN_PFA, a substantial proportion of patients with EPN_PFB can be cured with surgery alone, and patients with relapsed EPN_PFB can often be treated successfully with delayed external-beam irradiation. Conclusion The most impactful biomarker for posterior fossa ependymoma is molecular subgroup affiliation, independent of other demographic or treatment variables. However, both EPN_PFA and EPN_PFB still benefit from increased extent of resection, with the survival rates being particularly poor for subtotally resected EPN_PFA, even with adjuvant radiation therapy. Patients with EPN_PFB who undergo gross total resection are at lower risk for relapse and should be considered for inclusion in a randomized clinical trial of observation alone with radiation reserved for those who experience recurrence.

Návaznosti

ROZV/20/LF/2015, interní kód MU
Název: LF - Příspěvek IP 2015
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, LF - Příspěvek IP 2015